SANDFORD D. SMITH

Corporate Board Profile

Tech Score: 0/100

CSP INC /MA/

Filing Date	Source Excerpt
2002-12-26	Sandford D. Smith (55) . . . . . . . . . . . Director of CSPI since 1993; President of Therapeutics International of Genzyme Corp., a biopharmaceutical company, since February 1997; President of Specialty Therapeutics of Genzyme Corp., from April 1996 to February 1997; President and Chief Executive Officer of Repligen Corporation from 1987 to 1996; Director of Ariad Pharmaceuticals, Inc. and Chemex Pharmaceuticals, Inc. The Audit Committee consists of Messrs. James, Smith and Williams. The Compensation Committee consists of Messrs. Lyons, James and Smith.

Filing Date

Source Excerpt

2002-12-26

Sandford D. Smith (55) . . . . . . . . . . . Director of CSPI since 1993; President of Therapeutics International of Genzyme Corp., a biopharmaceutical company, since February 1997; President of Specialty Therapeutics of Genzyme Corp., from April 1996 to February 1997; President and Chief Executive Officer of Repligen Corporation from 1987 to 1996; Director of Ariad Pharmaceuticals, Inc. and Chemex Pharmaceuticals, Inc. The Audit Committee consists of Messrs. James, Smith and Williams. The Compensation Committee consists of Messrs. Lyons, James and Smith.

CYTOKINETICS INC

Filing Date	Source Excerpt
2019-04-03	Sandford D. Smith Class II Audit Committee member Compensation and Talent Committee member 2018 compensation: $272,729 Director Compensation section
2020-03-26	Sandford D. Smith 72 Class II Audit Committee 37,500 162,154 199,654
2021-04-07	The following table sets forth the names of each member of our Board of Directors, their age, position, director class and committee membership as of April 1, 2021. Director Age Position/Class Audit Committee Compensation and Talent Committee Nominating and Governance Committee Science and Technology Committee Sandford D. Smith 74 Class II ✓ ✓
2023-04-07	The Compensation and Talent Committee consists of directors Mr. Costa (Chair), Mr. Smith, Dr. Wierenga and Ms. Wysenski. The Compliance Committee consists of directors Ms. Wysenski (Chair), Ms. Bhanji, Mr. Costa, Ms. Parshall, and Mr. Smith.
2024-04-08	Sandford D. Smith has served as a member of our Board of Directors since March 2012. Since December 2011, Mr. Smith has served as Founder and Chairman of Global Biolink Partners. From 1996 to 2011, Mr. Smith held various positions at Sanofi-Genzyme (formerly Genzyme Corporation), most recently leading the integration of Genzyme’s international business into Sanofi’s global organization. Prior to that, he served as Executive Vice President of Genzyme Corporation and President of Genzyme International. From 1986 to 1996, Mr. Smith was President, Chief Executive Officer and a member of the Board of Directors of RepliGen Corporation. From 1977 to 1985, Mr. Smith held various positions at Bristol-Myers Squibb, most recently serving as Vice President of Business Development and Strategic Planning for the Pharmaceutical and Nutritional Division. Mr. Smith served on the Board of Directors of Akcea Therapeutics, Inc. from 2017 until completion of its acquisition in October 2020 and on the Board of Directors of Neuralstem, Inc. from May 2014 to 2019. He served on the Board of Directors of Arpicus Biosciences, Inc. from August 2014 to February 2019, Novelion Therapeutics Inc. from November 2016 to March 2017, Aegerion Pharmaceuticals, Inc. from January 2012 to March 2017 and NVenta Biopharmaceuticals Corporation from 2007 to 2009. Mr. Smith earned a B.S. from the University of Denver.

PALISADE BIO, INC.

Filing Date	Source Excerpt
2015-04-27	Mr. Sandford D. Smith, has served on our board of directors since March 2014. Since December 2011, Mr. Smith has served as Founder and Chairman of Global Biolink Partners. From 1996 until 2011, Mr. Smith served in various senior and executive management positions at Genzyme Corporation (Formerly NASDAQ: GENZ), including Executive Vice President and President, International Group with responsibility for the commercial activities for Genzyme’s products outside of the U.S.
2016-04-28	Mr. Smith served in various senior and executive management positions at Genzyme Corporation, including Executive Vice President and President, International Group. He also served as President and CEO of Repligen Corporation, a biotechnology company.
2017-05-01	Mr. Smith served in various senior and executive management positions at Genzyme Corporation and was President and CEO of Repligen Corporation.
2018-04-25	Mr. Smith has served in various senior and executive management positions at Genzyme Corporation and other biotech companies.
2019-04-29	Mr. Smith served in various senior and executive management positions at Genzyme Corporation, including Executive Vice President and President, International Group.

Source material: SEC submissions metadata and DEF 14A proxy filings from EDGAR. Last updated: 2026-03-22